AtriCure Completes Acquisition of Estech

  AtriCure Completes Acquisition of Estech

Business Wire

WEST CHESTER, Ohio -- January 2, 2014

AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device
provider, today announced the completion of the previously announced
acquisition of Endoscopic Technologies, Inc. d/b/a Estech (“Estech”). Estech
develops and markets a portfolio of innovative surgical ablation devices that
enable physicians to perform a variety of traditional and minimally invasive
procedures using Estech’s proprietary temperature controlled RF energy.

“We are pleased to complete the acquisition of Estech, and we welcome the team
to AtriCure. This transaction provides substantial benefits to AtriCure and
strengthens our leadership position in the atrial fibrillation market; we are
excited about the opportunities that our combined businesses will bring to our
customers,” said Mike Carrel, President and Chief Executive Officer of

AtriCure expects that the transaction will increase sales and marketing
expense as well as research and development expenditures in order to
accelerate clinical development and commercial sales of the combined product
portfolio. While these expenses will increase on absolute dollar basis,
AtriCure expects these expenses to decrease as a percentage of sales beginning
in 2015. AtriCure expects the transaction to be dilutive to earnings in 2014
and accretive in 2015 and beyond.


Piper Jaffray is acting as exclusive financial advisor, and Keating Muething &
Klekamp PLL is serving as legal counsel, to AtriCure. Leerink Swann is acting
as exclusive financial advisor, and DLA Piper LLP is serving as legal counsel,
to Estech.

About Estech

Estech develops and markets a portfolio of innovative medical devices that
enable cardiac surgeons to perform a variety of surgical procedures, while
specializing in minimally invasive and hybrid ablation. The company’s COBRA
line comprises a number of first‐ever ablation technologies invented,
developed, and brought exclusively to market by Estech. These include
temperature‐controlled RF energy delivery, Versapolar™ devices that provide
both bipolar and monopolar energy, suction‐applied tissue contact, and
internally‐cooled devices which provide superior ablation performance compared
to other ablation systems. For more information, please visit

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates (including projections and guidance), other
predictions of financial performance, launches by AtriCure of new products and
market acceptance of AtriCure’s products. Forward-looking statements are based
on AtriCure’s experience and perception of current conditions, trends,
expected future developments and other factors it believes are appropriate
under the circumstances and are subject to numerous risks and uncertainties,
many of which are beyond AtriCure’s control. These risks and uncertainties
include the rate and degree of market acceptance of AtriCure’s products,
AtriCure’s ability to develop and market new and enhanced products, the timing
of and ability to obtain and maintain regulatory clearances and approvals for
its products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, AtriCure’s ability to consummate acquisitions
or, if consummated, to successfully integrate acquired businesses into
AtriCure’s operations, AtriCure’s ability to recognize the benefits of
acquisitions, including potential synergies and cost savings, failure of an
acquisition or acquired company to achieve its plans and objectives generally,
risk that proposed or consummated acquisitions may disrupt operations or pose
difficulties in employee retention or otherwise affect financial or operating
results, competition from existing and new products and procedures or
AtriCure’s ability to effectively react to other risks and uncertainties
described from time to time in AtriCure’s SEC filings, such as fluctuation of
quarterly financial results, reliance on third party manufacturers and
suppliers, litigation or other proceedings, government regulation and stock
price volatility. AtriCure does not guarantee any forward-looking statement,
and actual results may differ materially from those projected. AtriCure
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. A further
list and description of risks, uncertainties and other matters can be found in
our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.


AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
Investor Relations Contact
Westwicke Partners
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.